Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202201931
Abstract: Pancreatic ductal adenocarcinoma (PDAC), one of the worst prognosis types of tumors, is characterized by dense extracellular matrix, which compresses tumor vessels and forms a physical barrier to inhibit therapeutic drug penetration and efficacy. Herein,… read more here.
Keywords: antihypertension; losartan; pancreatic cancer; perfusion ... See more keywords
Losartan for the nephropathy of sickle cell anemia: A phase‐2, multicenter trial
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24810
Abstract: Nephropathy is a common and progressive complication of sickle cell anemia (SCA). In SCA mice, we found that hyperangiotensinemia in the absence of hypertension underlies nephropathy, and its downregulation by losartan, an angiotensin‐II‐receptor‐1 blocker, reduced… read more here.
Keywords: trial; losartan nephropathy; losartan; cell anemia ... See more keywords
Losartan protects against osteoarthritis by repressing the TGF-β1 signaling pathway via upregulation of PPARγ
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Orthopaedic Translation"
DOI: 10.1016/j.jot.2021.03.005
Abstract: Objective Losartan and activation of the peroxisome proliferator-activated receptor-γ (PPARγ) have been previously reported to alleviate the progression of osteoarthritis (OA). However, the nature of the interaction between losartan and PPARγ in OA remains elusive.… read more here.
Keywords: ppar; treatment; losartan; signaling pathway ... See more keywords
Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling and function in a prehypertensive rat model
Sign Up to like & getrecommendations! Published in 2017 at "Life Sciences"
DOI: 10.1016/j.lfs.2017.01.013
Abstract: Aims: Pharmacological treatment of prehypertension may ameliorate hypertension and improve vascular structure and function. This study investigated 1) whether early treatment with either losartan or amlodipine at the onset of prehypertension can prevent hypertension and… read more here.
Keywords: treatment; losartan; remodeling function; vascular remodeling ... See more keywords
Losartan Rescues Inflammation-Related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Sign Up to like & getrecommendations! Published in 2019 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.201905-0990oc
Abstract: RATIONALE Despite therapeutic progress in treating cystic fibrosis (CF) airway disease, airway inflammation with associated mucociliary dysfunction remains largely unaddressed. Inflammation reduces the activity of apically expressed large conductance, Ca2+-activated and voltage-dependent K+ channels (BK),… read more here.
Keywords: cystic fibrosis; dysfunction; mucociliary dysfunction; inflammation ... See more keywords
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.202201-0206oc
Abstract: RATIONALE There are no pharmacologic agents that modify emphysema progression in patients with chronic obstructive pulmonary disease (COPD). OBJECTIVE Evaluate the efficacy of losartan, an angiotensin receptor blocker (ARB), to reduce emphysema progression. METHODS The… read more here.
Keywords: losartan; emphysema progression; emphysema; trial ... See more keywords
Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0220903
Abstract: There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth… read more here.
Keywords: limb girdle; losartan; model; dysferlin null ... See more keywords